Toll Free: 1-888-928-9744

Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 53 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016', provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted pipeline therapeutics. 

The report provides comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)
- The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) Overview 7 Therapeutics Development 8 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Stage of Development 8 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Therapy Area 9 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Indication 10 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Companies 13 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Universities/Institutes 15 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Companies Involved in Therapeutics Development 24 Bayer AG 24 Bristol-Myers Squibb Company 25 Cambryn Biologics LLC 26 eXithera Pharmaceuticals, Inc 27 Ionis Pharmaceuticals, Inc. 28 LegoChem Biosciences, Inc 29 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Drug Profiles 30 AB-022 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 BAY-1213790 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 BMS-262084 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 BMS-654457 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 coagulation factor XI (human) - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 coagulation factor XI (human) - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 IONIS-FXIRx - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecule 2 to Inhibit Factor XIa for Thrombosis - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecules to Inhibit Factor XIa for Cardiovascular - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecules to Inhibit Factor XIa for Stroke and Thrombosis - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Dormant Projects 44 Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Featured News & Press Releases 45 Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 45 Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022 45 Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 46 Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 47 May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 47 Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma 48 Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery 49 Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding 49 Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders 51 Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by Bayer AG, H1 2016 24 Pipeline by Bristol-Myers Squibb Company, H1 2016 25 Pipeline by Cambryn Biologics LLC, H1 2016 26 Pipeline by eXithera Pharmaceuticals, Inc, H1 2016 27 Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 28 Pipeline by LegoChem Biosciences, Inc, H1 2016 29 Dormant Projects, H1 2016 44


List of Figures
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Mechanism of Actions, H1 2016 18 Number of Products by Stage and Mechanism of Actions, H1 2016 18 Number of Products by Routes of Administration, H1 2016 20 Number of Products by Stage and Routes of Administration, H1 2016 20 Number of Products by Molecule Types, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 22

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...

Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commerc

Read More...

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify